Clinical Stage Drug Discovery Based on Our Proprietary Platform Technology

SMNH: Delivering Novel Chemistry Solutions for Today's Diseases

SB 9200: A Potential Breakthrough Drug for HBV

Latest News

    • 22 AUG 16

    Spring Bank Pharmaceuticals, Inc. to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13th, 2016

    HOPKINTON, Mass., Aug. 22, 2016 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced it will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 13th at 11:40 am ET. Martin Driscoll, President and CEO of Spring Bank Pharmaceuticals, will provide an overview of the Company’s business during the live presentation and Jon Freve, CFO, will also be in attendance.

    In addition to the presentation, management will be available to participate in one-on-one meetings with qual…

    Read more →
    • 01 AUG 16

    Spring Bank Pharmaceuticals Announces Second Quarter 2016 Financial Results and Recent Highlights

    HOPKINTON, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced second quarter 2016 financial results and provided an update on recent corporate and clinical developments.

    “We made good progress in the second quarter, achieving two major milestones for our company with the completion of our initial public offering and the dosing of the first patient in our ACHIEVE Phase 2a clinical trial of our lead compound, SB 9200, in Hepatitis B,” said Martin Driscoll, President and Chief Executive Offic…

    Read more →